Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1
- PMID: 3092113
- DOI: 10.1038/323086a0
Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1
Abstract
Activated monocytes or macrophages can release soluble cytotoxic molecules capable of lysing tumour cells in vitro and thus represent an important component of the host defence mechanisms against malignancy. The recent availability of pure recombinant or natural human lymphokines and monokines and their respective polyclonal or monoclonal antibodies now makes it possible to dissect the interactions of these factors in the induction and performance of the cytotoxic event by the monocytes. Our studies indicate that pretreatment of monocytes with alpha-IFN or gamma-IFN, and also interleukin (IL)-1 or tumour necrosis factor (TNF) results in enhanced monocyte cytotoxicity. Although all these substances induce the production of IL-1 by monocytes, TNF mediates the enhanced cytotoxicity induced in monocytes by gamma-IFN, IL-1 and, in an autocrine manner, by TNF itself. Neither TNF, IL-1, gamma-IFN nor alpha-IFN mediate spontaneous monocyte cytotoxicity or that induced by alpha-IFN. Our studies thus reveal new interactions between the two monokines IL-1 and TNF and provide a dual role for TNF, as immunomodulator and mediator of monocyte cytotoxicity induced by certain specific lymphokine and monokine molecules.
Similar articles
-
Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages.Cancer Res. 1989 May 15;49(10):2606-14. Cancer Res. 1989. PMID: 2496917
-
Lipopolysaccharide and interleukin 1 inhibit interferon-gamma-induced Fc receptor expression on human monocytes.J Immunol. 1987 Sep 15;139(6):1873-9. J Immunol. 1987. PMID: 2957441
-
IFN-alpha and IFN-gamma can affect both monocytes and tumor cells to modulate monocyte-mediated cytotoxicity.J Immunol. 1990 May 1;144(9):3643-8. J Immunol. 1990. PMID: 2158515
-
Monocyte deactivation--rationale for a new therapeutic strategy in sepsis.Intensive Care Med. 1996 Oct;22 Suppl 4:S474-81. doi: 10.1007/BF01743727. Intensive Care Med. 1996. PMID: 8923092 Review.
-
Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.Lab Invest. 1987 Mar;56(3):234-48. Lab Invest. 1987. PMID: 3029503 Review. No abstract available.
Cited by
-
Sex-Based Differences in the Cytokine Production and Intracellular Signaling Pathways in Patients With Rheumatoid Arthritis.Arch Rheumatol. 2020 Apr 27;35(4):545-557. doi: 10.46497/ArchRheumatol.2020.7481. eCollection 2020 Dec. Arch Rheumatol. 2020. PMID: 33758811 Free PMC article.
-
Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells.Proc Natl Acad Sci U S A. 1988 Jul;85(14):5102-6. doi: 10.1073/pnas.85.14.5102. Proc Natl Acad Sci U S A. 1988. PMID: 2899323 Free PMC article.
-
Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis.Rheumatol Int. 2006 Oct;26(12):1125-31. doi: 10.1007/s00296-006-0147-y. Epub 2006 Jun 24. Rheumatol Int. 2006. PMID: 16799778 Clinical Trial.
-
Infusions of interleukin-1 alpha after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity.J Clin Immunol. 1994 May;14(3):205-11. doi: 10.1007/BF01533369. J Clin Immunol. 1994. PMID: 7929695 Clinical Trial.
-
Syndecan-1 is an in vivo suppressor of Gram-positive toxic shock.J Biol Chem. 2008 Jul 18;283(29):19895-903. doi: 10.1074/jbc.M801614200. Epub 2008 May 22. J Biol Chem. 2008. PMID: 18499671 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources